Summary of Structure Therapeutics Conference Call on Eleniglipron Company Overview - **Company**: Structure Therapeutics (NasdaqGM: GPCR) - **Product**: Eleniglipron, an oral small molecule GLP-1 receptor agonist - **Focus**: Chronic weight management and obesity treatment Key Industry Insights - **Obesity Market**: - Current injectable peptides serve approximately 5 million people in the U.S., a small fraction of over 100 million people living with obesity or overweight [5][4] - By 2030, around 1.5 billion people globally are expected to be living with obesity or overweight [5] - **Need for Oral Medications**: - Oral small molecules like Eleniglipron can scale to meet the needs of the global patient population [6] Core Findings from Clinical Trials - **ACCESS Phase 2b Study Results**: - At 36 weeks, patients on Eleniglipron experienced placebo-adjusted weight loss of: - 8.2% (45 mg) - 9.8% (90 mg) - 11.3% (120 mg) [7] - In the exploratory ACCESS 2 study, patients on the 120 mg dose experienced a 14.1% placebo-adjusted weight loss [8] - Higher doses (180 mg and 240 mg) showed even greater weight loss of 14.4% and 15.3%, respectively [8] - No evidence of weight loss plateau beyond 36 weeks [8] - **Safety and Tolerability**: - Overall treatment discontinuation rate due to adverse events was 10.4% [9] - No events of drug-induced liver injury reported among over 500 patients treated [10] - Nausea peaked early in the titration phase but remained below 10% by the end of the study [17][19] - Improved tolerability observed with a lower starting dose of 2.5 mg, showing no treatment discontinuations in the first 10 weeks [34][39] Future Development Plans - **Phase 3 Readiness**: - Structure Therapeutics is preparing to move into Phase 3 trials, with an anticipated mid-2026 first patient in [40] - Plans to initiate Phase 3 studies using a 2.5 mg starting dose based on improved tolerability data [41] - **Combination Therapies**: - Eleniglipron is positioned as a backbone for future oral combination therapies [6] - Structure Therapeutics is also developing amylin-targeted molecules and exploring potential indications beyond obesity [42][43] Market Positioning - **Target Audience**: - Focus on primary care physicians and non-specialists who seek effective, convenient, and accessible treatment options for obesity [41] - **Competitive Advantage**: - Eleniglipron's oral formulation and favorable safety profile position it as a potential best-in-class option in the growing chronic weight management market [41] Upcoming Catalysts - **2026 Milestones**: - End of Phase 2 meeting with the FDA - Top-line results from ongoing studies - Initiation of pivotal Phase 3 studies for Eleniglipron [44][45] Conclusion - Eleniglipron demonstrates significant potential in the obesity treatment landscape, with compelling efficacy and a favorable safety profile, setting the stage for its advancement into Phase 3 clinical trials and broader market introduction.